Keros Therapeutics Inc
KROS
View Detailed Chart
21.030USD
-0.330-1.54%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
854.49MMarket Cap
13.21P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.54%
5 Days
+3.80%
1 Month
+20.17%
6 Months
+55.89%
Year to Date
+32.85%
1 Year
+28.08%
View Detailed Chart
TradingKey Stock Score of Keros Therapeutics Inc
Currency: USD Updated: 2025-12-26Key Insights
Keros Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 8/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.38.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Keros Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
11
analysts
Buy
Current Rating
23.375
Target Price
+9.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Keros Therapeutics Inc Highlights
StrengthsRisks
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.55M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.55M.
Overvalued
The company’s latest PE is 13.21, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 41.03M shares, decreasing 30.26% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.65K shares of this stock.
Keros Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Keros Therapeutics Inc Info
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Ticker SymbolKROS
CompanyKeros Therapeutics Inc
CEOSeehra (Jasbir)
Websitehttps://www.kerostx.com/
FAQs
What is the current price of Keros Therapeutics Inc (KROS)?
The current price of Keros Therapeutics Inc (KROS) is 21.030.
What is the symbol of Keros Therapeutics Inc?
The ticker symbol of Keros Therapeutics Inc is KROS.
What is the 52-week high of Keros Therapeutics Inc?
The 52-week high of Keros Therapeutics Inc is 22.550.
What is the 52-week low of Keros Therapeutics Inc?
The 52-week low of Keros Therapeutics Inc is 9.120.
What is the market capitalization of Keros Therapeutics Inc?
The market capitalization of Keros Therapeutics Inc is 854.49M.
What is the net income of Keros Therapeutics Inc?
The net income of Keros Therapeutics Inc is -187.35M.
Is Keros Therapeutics Inc (KROS) currently rated as Buy, Hold, or Sell?
According to analysts, Keros Therapeutics Inc (KROS) has an overall rating of Buy, with a price target of 23.375.
What is the Earnings Per Share (EPS TTM) of Keros Therapeutics Inc (KROS)?
The Earnings Per Share (EPS TTM) of Keros Therapeutics Inc (KROS) is 1.593.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%Popular Symbols
